Replies to post #171669 on Biotech Values

[ciotera]

clearly second-rate drug

Well you could look at differently. Victrelis actually had quite a bit going for it - the combined muscle of Merck/Schering and Roche plus the pricing advantage, VA contract and still only got 25% against an arguably equally efficacious treatment.